Bowling Portfolio Management LLC bought a new stake in shares of Amedisys Inc (NASDAQ:AMED) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 40,711 shares of the health services provider’s stock, valued at approximately $2,146,000. Bowling Portfolio Management LLC owned approximately 0.12% of Amedisys at the end of the most recent reporting period.
Other institutional investors have also made changes to their positions in the company. Mitsubishi UFJ Asset Management UK Ltd. raised its stake in shares of Amedisys by 15.6% in the 4th quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 22,200 shares of the health services provider’s stock worth $1,170,000 after buying an additional 3,000 shares in the last quarter. Fox Run Management L.L.C. acquired a new position in shares of Amedisys in the 4th quarter worth $269,000. Acadian Asset Management LLC grew its holdings in shares of Amedisys by 47.3% in the 4th quarter. Acadian Asset Management LLC now owns 51,596 shares of the health services provider’s stock worth $2,719,000 after acquiring an additional 16,563 shares during the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of Amedisys by 1.9% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 176,363 shares of the health services provider’s stock worth $9,297,000 after acquiring an additional 3,315 shares during the last quarter. Finally, DnB Asset Management AS acquired a new position in shares of Amedisys in the 4th quarter worth $3,722,000. 93.73% of the stock is currently owned by hedge funds and other institutional investors.
Amedisys Inc (NASDAQ:AMED) traded up $1.02 during midday trading on Wednesday, reaching $56.05. The company had a trading volume of 249,922 shares, compared to its average volume of 349,301. The company has a market cap of $1,878.40, a price-to-earnings ratio of 44.84, a PEG ratio of 1.16 and a beta of 0.73. Amedisys Inc has a 1-year low of $45.60 and a 1-year high of $65.91. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.33 and a current ratio of 1.33.
A number of research analysts have recently weighed in on AMED shares. Royal Bank of Canada reiterated a “hold” rating on shares of Amedisys in a report on Monday, October 23rd. Robert W. Baird lifted their price objective on Amedisys from $50.00 to $60.00 and gave the company a “neutral” rating in a research report on Friday, November 10th. SunTrust Banks reissued a “buy” rating and set a $70.00 price objective on shares of Amedisys in a research report on Friday, November 10th. William Blair reaffirmed an “outperform” rating on shares of Amedisys in a research report on Tuesday, November 21st. Finally, BidaskClub cut Amedisys from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 11th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the stock. Amedisys presently has a consensus rating of “Hold” and a consensus price target of $60.64.
COPYRIGHT VIOLATION WARNING: “40,711 Shares in Amedisys Inc (AMED) Purchased by Bowling Portfolio Management LLC” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/14/40711-shares-in-amedisys-inc-amed-purchased-by-bowling-portfolio-management-llc.html.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.